121:. The group believes that good communication between all these disciplines is how ideas can be turned into improvements for patients. 2013 marked new developments for IOTA. Having focused on research, the group had the first IOTA congress and the development of the IOTA website. Having established a platform of clinical research centres IOTA will be planning further studies investigating aspects of ovarian cancer management and outcome prediction. Interested units should contact the group and we are always interested in new ideas!
17:
76:". These can be applied in about 75% of masses. For the remainder, a further scan by a sub-specialist is recommended. Another approach has to use simple descriptors, which are intuitive features of masses that an ultrasound examiner can use to easily classify about 50% of masses. Summaries of the IOTA studies have been published as reviews.
25:
505:
Sayasneh, A; Kaijser, J; Preisler, J; Johnson, S; Stalder, C; Husicka, R; Guha, S; Naji, O; Abdallah, Y; Raslan, F; Drought, A; Smith, A. A.; Fotopoulou, C; Ghaem-Maghami, S; Van
Calster, B; Timmerman, D; Bourne, T (2013). "A multicenter prospective external validation of the diagnostic performance
63:
Having agreed on standardised terminology the principal IOTA investigators prospectively studied a large cohort of patients with a persistent adnexal mass in several different clinical centres. This database and the close involvement of the civil engineering department at KU Leuven has enabled both
96:
to name but a few (IOTA phase 3). Finally a clinical trial is taking place in London (IOTA phase 4) to evaluate the performance of IOTA prediction models and rules in the hands of examiners with different levels of experience and training. Two paper have been published from the IOTA 4 study that
79:
Currently IOTA is engaged in several new studies. The group are studying the long-term behaviour of expectantly managed adnexal pathology (IOTA phase 5). This will answer important questions about complications and malignant transformation in masses that are left in situ. A number of studies are
326:
Ameye, L; Timmerman, D; Valentin, L; Paladini, D; Zhang, J; Van
Holsbeke, C; Lissoni, A. A.; Savelli, L; Veldman, J; Testa, A. C.; Amant, F; Van Huffel, S; Bourne, T (2012). "Clinically oriented three-step strategy for assessment of adnexal pathology".
100:
Today there are over 50 clinical units contributing to IOTA studies in nearly every continent. The culture of IOTA is to be transparent and open to new collaborators. The group is multidisciplinary and involves
64:
previously developed prediction models to be tested and novel prediction models to be developed and externally validated . In this way IOTA has been able to refine the optimal approach to characterise adnexal
243:
Timmerman, D; Testa, A. C.; Bourne, T; Ferrazzi, E; Ameye, L; Konstantinovic, M. L.; Van
Calster, B; Collins, W. P.; Vergote, I; Van Huffel, S; Valentin, L; International Ovarian Tumor Analysis Group (2005).
456:; Preisler, J; Kaijser, J; Johnson, S; Stalder, C; Husicka, R; Abdallah, Y; Raslan, F; Drought, A; Smith, A. A.; Ghaem-Maghami, S; Epstein, E; Van Calster, B; Timmerman, D; Bourne, T (2013).
285:
Van
Holsbeke, C; Van Calster, B; Bourne, T; Ajossa, S; Testa, A. C.; Guerriero, S; Fruscio, R; Lissoni, A. A.; Czekierdowski, A; Savelli, L; Van Huffel, S; Valentin, L; Timmerman, D (2012).
246:"Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: A multicenter study by the International Ovarian Tumor Analysis Group"
204:"Terms, definitions and measurements to describe the sonographic features of adnexal tumors: A consensus opinion from the International Ovarian Tumor Analysis (IOTA) group"
48:, Sweden). Its first aim was to develop standardised terminology, and in 2000 IOTA published a consensus statement on terms, definitions and measurements to describe the
202:
Timmerman, D.; Valentin, L.; Bourne, T. H.; Collins, W. P.; Verrelst, H.; Vergote, I.; International
Ovarian Tumor Analysis (IOTA) Group (2000).
155:
80:
being carried out on masses that currently are difficult to classify even for the most experienced examiner. These studies involve the use of
370:
Kaijser, J; Bourne, T; Valentin, L; Sayasneh, A; Van
Holsbeke, C; Vergote, I; Testa, A. C.; Franchi, D; Van Calster, B; Timmerman, D (2013).
413:"Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: A systematic review and meta-analysis"
372:"Improving strategies for diagnosing ovarian cancer: A summary of the International Ovarian Tumor Analysis (IOTA) studies"
56:
that is now widely used today. IOTA now comprises one of a portfolio of studies examining many aspects of gynaecological
145:
60:
and early pregnancy within a network of contributing centres throughout the world that are coordinated from KU Leuven
547:
138:
41:
411:
Kaijser, J; Sayasneh, A; Van Hoorde, K; Ghaem-Maghami, S; Bourne, T; Timmerman, D; Van
Calster, B (2013).
458:"Multicentre external validation of IOTA prediction models and RMI by operators with varied training"
68:
preoperatively. IOTA has also described simple ultrasound based rules that can be used to classify
352:
287:"External validation of diagnostic models to estimate the risk of malignancy in adnexal masses"
523:
487:
434:
393:
344:
308:
267:
225:
164:
515:
477:
469:
424:
383:
336:
298:
257:
215:
57:
45:
482:
457:
102:
73:
541:
453:
220:
203:
33:
356:
69:
53:
303:
286:
97:
suggest that IOTA rules and models to work when they are not applied by experts.
519:
106:
49:
110:
89:
85:
262:
245:
429:
412:
131:
118:
114:
65:
37:
527:
491:
438:
397:
348:
312:
271:
229:
16:
473:
81:
506:
of IOTA simple descriptors and rules to characterize ovarian masses".
388:
371:
340:
24:
23:
15:
93:
182:
177:
36:
Analysis (IOTA) group was formed in 1999 by Dirk
Timmerman (
28:
Ben Van
Calster - the lead statistician for the IOTA project
20:
Members of the IOTA group at the biannual meeting in Leuven
8:
481:
428:
387:
376:Ultrasound in Obstetrics & Gynecology
329:Ultrasound in Obstetrics & Gynecology
302:
261:
219:
208:Ultrasound in Obstetrics and Gynecology
194:
130:Dirk Timmerman, University Hospitals,
148:Malmö, Lund University, Malmö, Sweden
7:
156:UniversitĂ Cattolica del Sacro Cuore
151:Ben Van Calster, KU Leuven, Belgium
161:Ignace Vergote, KU Leuven, Belgium
14:
44:, London, UK), and Lil Valentin (
221:10.1046/j.1469-0705.2000.00287.x
141:, London and KU Leuven, Belgium
1:
304:10.1158/1078-0432.CCR-11-0879
250:Journal of Clinical Oncology
520:10.1016/j.ygyno.2013.04.003
564:
462:British Journal of Cancer
417:Human Reproduction Update
146:SkĂĄne University Hospital
291:Clinical Cancer Research
263:10.1200/JCO.2005.01.7632
40:, Belgium), Tom Bourne (
139:Imperial College London
125:IOTA steering committee
42:Imperial College London
29:
21:
430:10.1093/humupd/dmt059
27:
19:
508:Gynecologic Oncology
474:10.1038/bjc.2013.224
167:, KU Leuven, Belgium
32:The International
30:
22:
389:10.1002/uog.12323
341:10.1002/uog.11177
165:Sabine Van Huffel
72:and so diagnose "
555:
532:
531:
502:
496:
495:
485:
449:
443:
442:
432:
408:
402:
401:
391:
367:
361:
360:
323:
317:
316:
306:
282:
276:
275:
265:
256:(34): 8794–801.
240:
234:
233:
223:
199:
563:
562:
558:
557:
556:
554:
553:
552:
538:
537:
536:
535:
504:
503:
499:
468:(12): 2448–54.
451:
450:
446:
410:
409:
405:
369:
368:
364:
325:
324:
320:
284:
283:
279:
242:
241:
237:
201:
200:
196:
191:
174:
154:Antonia Testa,
127:
58:ultrasonography
46:Lund University
12:
11:
5:
561:
559:
551:
550:
548:Ovarian cancer
540:
539:
534:
533:
497:
444:
403:
362:
318:
277:
235:
214:(5): 500–505.
193:
192:
190:
187:
186:
185:
183:iota.education
180:
173:
170:
169:
168:
162:
159:
152:
149:
144:Lil Valentin,
142:
135:
126:
123:
103:gynaecologists
74:ovarian cancer
54:adnexal masses
13:
10:
9:
6:
4:
3:
2:
560:
549:
546:
545:
543:
529:
525:
521:
517:
513:
509:
501:
498:
493:
489:
484:
479:
475:
471:
467:
463:
459:
455:
452:Sayasneh, A;
448:
445:
440:
436:
431:
426:
423:(3): 449–62.
422:
418:
414:
407:
404:
399:
395:
390:
385:
381:
377:
373:
366:
363:
358:
354:
350:
346:
342:
338:
335:(5): 582–91.
334:
330:
322:
319:
314:
310:
305:
300:
297:(3): 815–25.
296:
292:
288:
281:
278:
273:
269:
264:
259:
255:
251:
247:
239:
236:
231:
227:
222:
217:
213:
209:
205:
198:
195:
188:
184:
181:
179:
178:iotagroup.org
176:
175:
172:IOTA websites
171:
166:
163:
160:
158:, Rome, Italy
157:
153:
150:
147:
143:
140:
136:
133:
129:
128:
124:
122:
120:
116:
113:– as well as
112:
108:
104:
98:
95:
91:
87:
83:
77:
75:
71:
70:ovarian cysts
67:
61:
59:
55:
51:
47:
43:
39:
35:
34:Ovarian Tumor
26:
18:
514:(1): 140–6.
511:
507:
500:
465:
461:
447:
420:
416:
406:
379:
375:
365:
332:
328:
321:
294:
290:
280:
253:
249:
238:
211:
207:
197:
137:Tom Bourne,
107:radiologists
99:
78:
62:
52:features of
31:
382:(1): 9–20.
111:oncologists
50:sonographic
454:Wynants, L
189:References
119:biologists
115:physicists
90:Biomarkers
86:proteomics
134:, Belgium
132:KU Leuven
84:imaging,
66:pathology
38:KU Leuven
542:Category
528:23578539
492:23674083
439:24327552
398:23065859
349:22511559
313:22114135
272:16314639
230:11169340
88:, novel
82:vascular
483:3694231
357:5295296
526:
490:
480:
437:
396:
355:
347:
311:
270:
228:
353:S2CID
524:PMID
488:PMID
435:PMID
394:PMID
345:PMID
309:PMID
268:PMID
226:PMID
117:and
92:and
516:doi
512:130
478:PMC
470:doi
466:108
425:doi
384:doi
337:doi
299:doi
258:doi
216:doi
94:MRI
544::
522:.
510:.
486:.
476:.
464:.
460:.
433:.
421:20
419:.
415:.
392:.
380:41
378:.
374:.
351:.
343:.
333:40
331:.
307:.
295:18
293:.
289:.
266:.
254:23
252:.
248:.
224:.
212:16
210:.
206:.
109:,
105:,
530:.
518::
494:.
472::
441:.
427::
400:.
386::
359:.
339::
315:.
301::
274:.
260::
232:.
218::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
